

# INFECTION PREVENTION & CONTROL 2017

Sharing knowledge, Improving care

**Wednesday 22nd February 2017**

The Brewery, Chiswell Street, London

## No-Touch Disinfection: The New Frontier in Patient Safety

SPONSORED BY:



[WWW.KNOWLEX.CO.UK](http://WWW.KNOWLEX.CO.UK)



#IPC2017

# No Touch Disinfection – The New Frontier in Patient Safety

Mark Stibich, PhD

Founder & Chief Scientific Officer - Xenex Disinfection Services, LLC

Visiting Scientist - MD Anderson Cancer Center



# About Xenex Disinfection Services

---

- Founded in 2009 by Mark Stibich and Julie Stachowiak, two PhDs from Johns Hopkins
- Number of employees: ~125
- Over 740 robots disinfecting 375+ hospitals
- Distribution in 18 countries
- Peer reviewed studies: 9 outcome studies, 5 environmental studies and 1 patient Satisfaction (HCAHPS) Study – and multiple studies in preparation.
- Primary market: acute care, post-acute care; LTACs, SNFS and ASCs

# DISCLOSURES

---

- Shareholder and Chief Scientific Officer for Xenex Disinfection Services, San Antonio, Texas




# OUTLINE

---

- The Role of the Environment in Transmission of Pathogens
- Evidence for Automated Disinfection
- Outcomes Data
- MD Anderson Cancer Center Experience

# WHERE ARE THE BUGS?



# WHERE ARE THE BUGS?



Crit Care Med. 2010 Aug;38(8 Suppl):S335-44. doi: 10.1097/CCM.0b013e3181e6ab12.

**Methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococcus: recognition and prevention in intensive care units.**

Lin MY<sup>1</sup>, Hayden MK.

# SPREAD OF MDROS:

## ROLE OF THE HEALTHCARE ENVIRONMENT

---

- Issue: Patients shed important pathogens including VRE, *C. difficile*, MRSA, and *Acinetobacter baumannii* into their surrounding environment.
- Problem: These organisms remain viable on inanimate objects for days to months, and can be transferred from the environment to HCWs hands, and then to other patients.
- Inadequate infection control propagates MDROs.
- Another Problem: Contamination of hospital rooms and equipment can persist despite cleaning and disinfection.

# KEY COMPONENTS OF AN INFECTION CONTROL PROGRAM

---


- **Surveillance Programs**
- **Implementation & Monitoring of Best Practices**
- **Environmental Cleaning**
- Antimicrobial Stewardship Program
- **Transmission-based Precautions**
- Patient-specific Factors
- Employees, Visitors and Caregivers

# HOW LONG DO PATHOGENS SURVIVE?

## Persistence of Microbes on Dry, Inanimate Surfaces

Pathogen	Duration of Persistence (range)
<i>S. aureus</i> , including MRSA	7 days – 7 months
<i>Enterococcus</i> spp., including VRE	5 days – 4 months
<i>C. difficile</i> spores	(5 months)
<i>Acinetobacter</i> spp., including MDR	3 days – 5 months
<i>C. albicans</i>	1 day – 4 months
<i>E. coli</i> , including ESBL	1.5 hours – 5 months
<i>Klebsiella</i> spp., including ESBL	2 hours – > 30 months
<i>Herpes simplex virus type 1 and 2</i>	4.5 hours – 2 months
<i>Norovirus</i>	8 hours – 7 days

Modified from: Kramer A et al, BMC Infectious Diseases 2006, 6:130.







**Q: Isn't housekeeping good enough?**

**A: No. ~50% surfaces missed**

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY JANUARY 2008, VOL. 29, NO. 1

ORIGINAL ARTICLE

## Identifying Opportunities to Enhance Environmental Cleaning in 23 Acute Care Hospitals

P. C. Carling, MD; M. E. Parry, MD; S. M. Von Beheren, RN, BSN, MS, CIC;  
for the Healthcare Environmental Hygiene Study Group

# ROOM CONTAMINATION

## Post-Discharge Cleaning

---

<b>PATHOGEN</b>	<b>% CONTAMINATED AFTER DISCHARGE CLEANING</b>
MRSA <sup>1</sup>	74% of Surface Cultures
MRSA <sup>2</sup>	46% of Rooms
MRSA <sup>3</sup>	24% of Rooms
VRE <sup>3</sup>	22% of Rooms
VRE <sup>4</sup>	16% of Rooms

<sup>1</sup> French GL et al. J Hosp Infect 2004;57:31-7

<sup>2</sup> Blythe D et al. J Hosp Infect 1998;38:67-70

<sup>3</sup> Goodman ER et al. ICHE 2008; 29:593-9

<sup>4</sup> Byers KE. ICHE 1998;19:261-4.

# **EVIDENCE FOR AUTOMATED DISINFECTION**

# ENHANCED ROOM DISINFECTION SYSTEMS

---

- Automated systems do not rely on the operator to ensure all surfaces are disinfected and adequate contact time is achieved
- However, it must be applied in addition to standard cleaning
- Require areas to be temporarily vacated of patients and staff and incur additional expense
- **TYPES:** Hydrogen Peroxide Vapor, Mercury UV light, Pulsed Xenon UV Light

# HYDROGEN PEROXIDE VAPOR (HPV)

---

- Reduces the risk of MDRO acquisition among high-risk patients who are admitted to a room previously occupied by a patient infected or colonized with an MDRO
- HPV in addition to a thorough infection prevention program could be implemented in high-risk environments to maximize patient safety

## **DRAWBACKS:**

- The time for disinfection is 1.5-3 hours per room<sup>1</sup>
- Did not reach statistically significant reduction in *C. diff*, MRSA or MDR-GNR<sup>1</sup>

1. Passaretti, et al. An Evaluation of Environmental Decontamination with Hydrogen Peroxide Vapor for Reducing the Risk of Patient Acquisition of Multidrug-Resistant Organisms. *Clinical Infectious Diseases (CID)*, January 2013

# UV LIGHT TECHNOLOGY

## Xenon vs. Mercury: Is All UV the Same?

---

	XENON	MERCURY
Bulb Type	Pulsed Xenon (non-toxic)	Mercury (toxic)
<i>C. diff</i> Kill Time	5 minutes	5 min. warm up + 45 min. + 15 min. cool down
MRSA Kill Time	2 minutes	5 min. warm up + 25 min. + 15 min. cool down
Intensity	High Intensity	Low Intensity
Spectrum	Wide Spectrum*	Narrow Spectrum

*\*Xenon emits light across full germicidal spectrum.*




# IS ALL UV THE SAME?

## Difference in Cell Damage

### STUDY OBSERVATIONS

- Pulsed xenon caused irreparable cell membrane damage (lysing).
- Pulsed xenon UV disinfected faster than mercury UV.



Cheigh C-I, Park M-H, Chung M-S, Shin J-K, Park Y-S: Comparison of intense pulsed light- and ultraviolet (UVC)-induced cell damage in *Listeria monocytogenes* and *Escherichia coli* O157:H7. *Food Control* 2012, 25:654-659.

# DUKE/UNC (BETR-D) STUDY

## BACKGROUND:

In 2010 CDC Prevention Epicenters Program approved funding for a study structured by Duke and overseen by researchers at Duke, DICON and UNC Chapel Hill. The study began in April of 2012.


- 9 devices
- 9 hospitals
- Randomized trial
- Isolation case focus

## RESULTS:

- No impact to *C. diff*
- The decrease in MRSA infections was not statistically significant
- Statistical significance for cumulative MDROs was driven by reductions in VRE

## Author's Commentary:


“Of four published studies on the clinical effectiveness of UV devices, one showed a 20% decrease in hospital-acquired multidrug-resistant organisms 23 and three showed 22–53% decreases in *C. difficile* infection.<sup>24–26</sup> In light of these results, we were surprised by the lack of change in rates of *C. difficile* among exposed patients.”



# IS ALL UV THE SAME?


## Material Compatibility is Different

---




# PULSED XENON UV LIGHT (PX-UV)

- 5-minute Sporicidal Cycle
- Outcome data on VRE, *C. diff*, SSI, MDROs and MRSA infection rate reductions




Levin AJIC 2013; Simons JIP 2013; Haas AJIC 2013; Miller, AJIC 2015; Fornwalt, AJIC 2015; Vianna, AJIC 2015

# ULTRAVIOLET DISINFECTION BEST PRACTICES



5 MINUTES IN EACH POSITION FOR PATIENT ROOMS



10 MINUTES IN EACH POSITION FOR OPERATING ROOMS

## DISINFECTING WITH LIGHT

Studies explain why multiple positions in a room are necessary for optimal room disinfection of high-touch surfaces.<sup>1</sup>

1-Boyce, J.M., N.L. Havill, and B.A. – Moore, Terminal decontamination of patient rooms using an automated room UV light unit. *Infect Control Hosp Epidemiol*, 2011 32(8): p. 737-42.



**Q: Is pulsed xenon UV dependent on housekeeping?**

**A: No, pulsed xenon UV is effective in absence of manual cleaning.**

American Journal of Infection Control xxx (2015) 1-4



ELSEVIER

Contents lists available at ScienceDirect

American Journal of Infection Control

journal homepage: [www.ajicjournal.org](http://www.ajicjournal.org)



Major article

**Is the pulsed xenon ultraviolet light no-touch disinfection system effective on methicillin-resistant *Staphylococcus aureus* in the absence of manual cleaning?**

Chetan Jinadatha MD, MPH <sup>a,b,\*</sup>, Frank C. Villamaria BS, MPH <sup>a,c</sup>,  
Marcos I. Restrepo MD <sup>d,e</sup>, Nagaraja Ganachari-Mallappa PhD <sup>a</sup>, I-Chia Liao BS <sup>a,c</sup>,  
Eileen M. Stock PhD <sup>f</sup>, Laurel A. Copeland PhD <sup>a,b,f</sup>, John E. Zeber PhD <sup>a,b,f</sup>

<sup>a</sup>Department of Medicine, Central Texas Veterans Healthcare System, Temple, TX

<sup>b</sup>Department of Medicine, College of Medicine, Texas A&M Health Science Center, Bryan, TX

<sup>c</sup>School of Public Health, Texas A&M University, College Station, TX

<sup>d</sup>Department of Medicine, South Texas Veterans Health Care System

<sup>e</sup>University of Texas Health Science Center San Antonio, San Antonio, TX

<sup>f</sup>Center for Applied Health Research, Temple, TX



# **OUTCOMES DATA**

# Peer Reviewed Published Infection Rate Reduction Studies

AUTHOR / YEAR / JOURNAL	ORGANISM	SETTING	INFECTION REDUCTION	SPECIAL CONSIDERATIONS
Miller et al, 2015. American Journal of Infection Control	<i>Clostridium difficile</i>	LTAC	56.90%	Estimated 29 cases prevented in 15 months
Nagaraja et al, 2015. American Journal of Infection Control	<i>Clostridium difficile</i>	ICU	70%	Estimated 30 cases prevented in 12 months
Haas et al, 2014. American Journal of Infection Control	Multiple MDROs	Whole House	20%	19% Gram- reduction, Estimated 185 cases prevented in 22 months
Levin et al, 2013. American Journal of Infection Control	<i>C. difficile</i>	Whole House	53%	Only 56% compliance to protocol
Simmons et al, 2013. Journal of Infection Prevention	MRSA	Healthcare System	57%	50:1 ROI, Estimated 58 cases prevented in 18 months
Vianna et al, 2015. American Journal of Infection Control	Multiple MDROs, <i>C. difficile</i>	Whole House	29%, 41%	All ICU discharges, <i>C. difficile</i> isolation facility wide
Catalanotti et al, 2016. American Journal of Infection Control	Class I SSIs	Operating Room	46%	Estimated 23 infections prevented over 21 months
Fornwalt et al, 2015. American Journal of Infection Control	Hip/Knee SSIs (Class I)	Operating Room	100%	Xenex used nightly after terminal cleaning

# A TRIAL OF PULSED XENON UV DISINFECTION TO REDUCE *C. DIFFICILE* INFECTION (MAYO CLINIC, ROCHESTER, MN)

---

- 39% decrease in CDI incidence on Xenex Units (p=0.03)
- No significant reduction in CDI incidence on control units.

	BEFORE INTERVENTION (6 MONTHS) April 2014 - September 2014				INTERVENTION (6 MONTHS) October 2014 - March 2015			
UNIT	CDI INCIDENCE	PATIENT DAYS	CDI RATE PER 10,000 PATIENT DAYS	P-VALUE	CDI INCIDENCE	PATIENT DAYS	CDI RATE PER 10,000 PATIENT DAYS	P-VALUE
PX-UV	15	8217	18.3	0.28	10	8958	11.2	0.03
CONTROL	11	5483	20.1		15	5219	28.7	

# TIMELINE FOR USE AT MD ANDERSON

---

- 2010 - Research
- 2011 - VRE Isolation Discharges (Three 5-minute Positions)
- 2012 - All Isolation Discharges Institution-wide (VRE, *C. diff*, MDR GNB)
- 2013 - All ICU Discharges
- 2013 - Elimination of Bleach for *C. diff* Terminal Clean
- 2014 - Continued Usage
- 2015 - ORs at Terminal Clean (Two 10-minute Positions)

# ENVIRONMENTAL STUDY: ELIMINATION OF VRE

## CURRENT HOUSEKEEPING METHODS VS. PULSED XENON UV FOR VRE ISOLATION ROOMS

ROOM STATUS	OBSERVATIONS	HPC MEAN (CFU/INCH <sup>2</sup> )	CONFIRMED VRE
PRE-CLEAN	75	213.7	17 (23%)
POST-HOUSEKEEPING	49	178.5	4 (8%)
POST-XENEX	75	7.8	0

***P = 0.0001***

*Stibich M, Stachowiak J, Tanner B, Berkheiser M, Moore L, Raad I, Chemaly RF. (2011). Infect Control Hosp Epidemiol. 32(3):286-8.*

# HOSPITAL OPERATIONAL STATISTICS FOR 8 PULSED XENON TREATED ROOMS

---

ACTIVITY	MINUTES
PX-UV travel time to room	3:48
Preparing the room	:15
PX-UV emittance	12:00
Safety countdown	1:30
Repositioning the PX-UV device	:31
Room exit	:44
<b>TOTAL PULSED XENON DISINFECTION TIME</b>	<b>18:48</b>

*Stibich M, et al. Infect Control Hosp Epidemiol. 2011; 32(3):286-288*



# ENVIRONMENTAL STUDY:

## Reducing *C. diff* Contamination Without Bleach

**Table 1.** Impact of standard cleaning and PX-UV disinfection on *Clostridium difficile* counts in patient rooms

Room status	Samples taken (n)	Samples positive for <i>C. difficile</i> [n (%)]	c.f.u.					Reduction (%)	P-value
			Min.	Mean	Median	Max.	IQR		
Pre-bleach	74	26 (35)	0	2.39	0	81	11	70	0.13
cleaning									
Post-bleach	74	18 (24)	0	0.71	0	18	0		
cleaning									
Pre-PX-UV	70	29 (41)	0	4.61	0	71	2	83	0.007
Cleaning									
Post-PX-UV	70	16 (23)	0	0.80	0	13	0		

IQR, Interquartile range.



# COMPLIANCE - EVS

- **WHO:** All rooms that housed patients with VRE, *C. difficile*, & Norovirus. All ICU patients. Also clusters or other situations, as deemed necessary by Infection Control.
- **WHERE:** Inpatient areas only
- **WHEN:** UV cleaning is auto assigned to patient room at discharge or transfer (via OneConnect), based on organism present at time of discharge. Most inpatient areas require 3 cycles at 4 minutes each cycle. Compliance measured monthly via device log upload to “Xenex portal”.
- **NOTE:** User ID must be entered for accountability.

Month	Total Patients Discharged Requiring PXUV	PXUV Performed When Required	% Compliant With Performing PXUV When Required	PXUV Performed Accurately (# of events/cycles)	% Compliant With PXUV Performed Correctly
AUG – 16	122	96	79%	65	68%
SEP – 16	77	69	90%	51	74%
OCT – 16	110	78	71%	59	76%
NOV – 16	98	87	89%	80	92%

# INCIDENCE OF ALL NOSOCOMIAL MDRO INFECTIONS

## FY11 to FY16

	FY11 NI	MDR NI/1000 pt days	FY12 NI	MDR NI/1000 pt days	FY13 NI	MDR NI/1000 pt days	FY14 NI	MDR NI/1000 pt days	FY15 NI	MDR NI/1000 pt days	FY16 NI	MDR NI/1000 pt days
<b>VRE</b>	38	0.211	32	0.167	32	0.158	42	0.207	29	0.143	17	0.086
<b>MRSA</b>	58	0.322	48	0.25	34	0.168	26	0.128	40	0.198	35	0.177
<b>MDR-Ps. aerug</b>	29	0.161	19	0.099	18	0.089	18	0.088	6	0.029	12	0.061
<b>ESBL-GNR</b>	42	0.233	42	0.219	39	0.193	40	0.197	45	0.222	44	0.223
<b>nonESBL GNR/CRE</b>	19/11	0.105	14/9	0.073	16/7	0.079	19/5	0.094	16/8	0.079	12/3	0.060
<b>Total MDR Nosocomial Infections</b>	186	<b>1.031</b>	155	<b>0.808</b>	139	<b>0.686</b>	145	<b>0.715</b>	136	<b>0.672</b>	120	<b>0.608</b>

# INCIDENCE OF ALL NOSOCOMIAL MDRO INFECTIONS FY11 to FY16

	FY11 NI	MDR NI/1000 pt days	FY12 NI	MDR NI/1000 pt days	FY13 NI	MDR NI/1000 pt days	FY14 NI	MDR NI/1000 pt days	FY15 NI	MDR NI/1000 pt days	FY16 NI	MDR NI/1000 pt days
VRE	38	0.211	32	0.167	32	0.158	42	0.207	29			0.086
MRSA	58	0.322	48	0.25	34	0.168	26				35	0.177
MDR-Ps. aerug	29	0.161	19	0.099	18				6	0.029	12	0.061
ESBL-GNR	42	0.233				0.193	40	0.197	45	0.222	44	0.223
nonESBL GNR/CRE			15	0.073	16/7	0.079	19/5	0.094	16/8	0.079	12/3	0.060
Total MDR Nosocomial Infections	186	1.031	155	0.808	139	0.686	145	0.715	136	0.672	120	0.608

**FY11 (1.031) TO FY16 (0.608) = 41% DECREASE IN RATE  
P < 0.001**

# CONCLUSIONS

---

- Manual cleaning is not adequate.
- The answer is not a single approach.
- We must blend technical knowledge with socio-adaptive skills.
- We must create a vision where prevention of harm, quality and safety is everyone's responsibility.

# THANK YOU!

